Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2026-04-22 Management Reports
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞2025年度独立董事述职报告（何为）
Management Reports Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告" which translates to "2025 Independent Director's Work Report." It is a detailed report by an independent director on their duties, attendance, and activities during the year 2025. The content includes descriptions of board meetings attended, committee participation, communication with auditors, and governance matters. It is a narrative report on management and board oversight activities rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or a regulatory filing. The document fits best under Management Reports (MDA) as it provides management's detailed explanation of governance, board activities, and oversight during the fiscal year.
2026-04-22 Chinese
神州细胞2025年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It is issued by a certified public accounting firm (ShineWing) and addresses the effectiveness of internal controls over financial reporting as of December 31, 2025. The content includes the auditor's responsibilities, the company's responsibilities, and an audit opinion on internal control effectiveness. The document is not a full annual report or financial statement but a standalone audit report focused on internal control. It is not a certification letter or a brief announcement but a detailed audit report. Therefore, it fits the category of Audit Report / Information (AR). The document length is 3953 characters, which is sufficient for a standalone audit report. Hence, the classification is AR with high confidence.
2026-04-22 Chinese
神州细胞2025年度独立董事述职报告（张学）
Board/Management Information Classification · 95% confidence The document is titled as the "2025年度独立董事述职报告" which translates to "2025 Annual Independent Director's Work Report". It details the independent director's duties, attendance at board and shareholder meetings, participation in committees, oversight of company governance, and evaluation of key corporate matters during the year 2025. The content focuses on the independent director's report on their activities and responsibilities fulfilled during the year, rather than presenting full financial statements or audit results. It is a detailed management-related report on governance and oversight activities by an independent director, which fits best under the category of Board/Management Information (MANG). The document length is under 5,000 characters, but it is a substantive report, not a mere announcement. It is not an audit report, annual report, or regulatory filing. Therefore, the classification is MANG with high confidence.
2026-04-22 Chinese
神州细胞关于会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (信永中和) in conducting the 2025 annual audit for the company. It details the auditor's qualifications, independence, quality control mechanisms, audit plan, resources, and overall assessment of the audit process. The document does not contain actual financial statements or results but rather an assessment of the auditor's work and quality management during the audit engagement. It is not the audit report itself, nor is it an annual report or interim report. The document is a standalone audit-related report focusing on the auditor's performance and internal controls, which fits the category of Audit Report / Information (AR). The document length is 3139 characters, which is relatively short but contains substantive content about audit quality and procedures, not just an announcement or certification. Therefore, the best classification is AR with high confidence.
2026-04-22 Chinese
神州细胞关于续聘公司2026年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2026. It details the auditor's qualifications, independence, audit fees, and the approval process by the audit committee and board of directors. There are no actual financial statements or audit results included, only information about the auditor appointment. The document length is short (2240 characters) and it serves as a formal announcement rather than the audit report itself. Therefore, it fits the category of Audit Report / Information (AR), which includes standalone audit reports and related announcements about audit firms, but not full annual reports or financial statements.
2026-04-22 Chinese
神州细胞董事会关于独立董事2025年度独立性自查情况的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the board regarding the independence self-assessment of independent directors for the year 2025. It references regulatory requirements related to independent directors and confirms their compliance with independence rules. The content focuses on governance and board oversight rather than financial results, audit, or shareholder voting. It is not a full report but a specific board/management announcement about director independence. Therefore, it fits best under Board/Management Information (MANG). The document length is short and does not contain financial data or voting results, so other categories like Annual Report, Audit Report, or Declaration of Voting Results are not applicable.
2026-04-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.